Research & Development

天无日天天射天天视天天啪天天舔天天透y大色窝中国新增一报警电话 110电话迎来“孪生兄弟”


  大部分,甚至是絕大部分人都認為雲氏的僕婦各個都是美人,至少,陳銅就是這樣認為的。   “智者嗎?”天无日天天射天天视   曹襄哭得非常傷心……天天啪天天舔天天透y   無所事事的蒙查很快就加入了這個隊伍。   不施脂粉的時候,一個個還能看,涂脂抹粉之後一個個就成了女妖怪。大色窝   劉陵大笑道︰“我的福根是我自己,其余的都不過是偽裝罷了。那個左吳不懷好意,時時慫恿我與單于決裂,看樣子他應該是劉徹派來的間諜,你們不要招惹他,就你們的心智,還經不起這個人的引誘。”

Our discovery and development platforms for drug and cell-based therapies allow us to both create and retain significant value within our therapeutic franchise areas of cancer and inflammatory diseases. Scientists and physicians at Celgene are the driving force behind our success, enabling target-to-therapeutic platforms that integrate both small-molecule and cell-based therapies.

Connect? Registries

The Connect??Registries are observational, hematologic patient registry studies in Multiple Myeloma (Connect?MM), Chronic Lymphocytic Leukemia (Connect?CLL) and Myelodysplastic Syndromes/Acute Myeloid Leukemia (Connect?MDS/AML) and are sponsored by Celgene Corporation. These studies are designed to observe the routine care of patients through the course of their disease. Unlike clinical trials, registries do not require or provide any specific medications or healthcare services, but leave those decisions to the treating doctors and their patients.
Connect? Registries logo